STOCK TITAN
  1. Home
  2. News
  3. TERN

Terns Pharmaceuticals, Inc. - TERN STOCK NEWS

Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.

The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.

One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.

Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.

Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.

For more information, please visit their website at www.ternspharma.com.

News

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced the appointment of Amy Burroughs as chief executive officer and her addition to the board of directors. Burroughs brings over 25 years of leadership experience, having led therapeutics and commercial strategies at various companies. Her appointment is aimed at advancing Terns' programs to later stage development and partnership, particularly in oncology and metabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
management
-
News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. granted an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended. The award consists of options to purchase 19,000 shares of Terns common stock with a 10-year term and an exercise price per share equal to $5.26. The options vest over four years, subject to the employee’s continued service through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
News

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) plans to advance its diverse pipeline of programs in oncology and metabolic diseases, with key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) anticipated in 2H24. The company is prioritizing capital allocation to its oncology and obesity programs, with cash and cash equivalents of $267M expected to provide runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) announced the granting of an equity inducement award to a new employee under the 2022 Employment Inducement Award Plan. The award consists of options to purchase 19,000 shares of Terns common stock at an exercise price of $6.49 per share, with a 10-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
News

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) to participate in fireside chat at JMP Securities Hematology and Oncology Summit. The clinical-stage biopharmaceutical company is developing small-molecule product candidates for serious diseases such as oncology, obesity, and NASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
conferences
-
News

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

Rhea-AI Summary
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: TERN), announced the passing of Senthil Sundaram, their recently retired CEO, on November 22, 2023. Sundaram had a distinguished career in the life sciences industry, serving as CFO of Nightstar Therapeutics plc and in various positions at Intercept Pharmaceuticals, Inc. Prior to joining Terns, he was involved in multiple private and public equity offerings and business development efforts. Memorial contributions may be made in his name to the Peritoneal Cancer Foundation (PCF) at Home. Sundaram's legacy lives on through the PCF, a charity he formed to support research and raise awareness of peritoneal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
none
News

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) reports progress in clinical development programs for CML, obesity, and NASH. Anticipates positive proof of concept readouts in 2024. Financial results show $267 million cash expected to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
earnings
-
News

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Rhea-AI Summary
TERN-501: Terns Pharmaceuticals Announces Positive Late-Breaking Data from Phase 2a DUET Clinical Trial for NASH Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
clinical trial
-
News

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

Rhea-AI Summary
TERN: Terns Pharmaceuticals Announces Participation in Investor Conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.89%
Tags
conferences
News

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. has granted equity inducement awards to three new non-executive employees under the Inducement Plan. The options to purchase 109,000 shares of Terns common stock were granted with a 10-year term and an exercise price of $5.25 per share. The options vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none

FAQ

What is the current stock price of Terns Pharmaceuticals (TERN)?

The current stock price of Terns Pharmaceuticals (TERN) is $4.46 as of January 31, 2025.

What is the market cap of Terns Pharmaceuticals (TERN)?

The market cap of Terns Pharmaceuticals (TERN) is approximately 375.4M.

What does Terns Pharmaceuticals, Inc. specialize in?

Terns Pharmaceuticals specializes in discovering and developing molecularly-targeted, oral, small-molecule drugs for liver diseases and cancers.

Where is Terns Pharmaceuticals located?

Terns Pharmaceuticals is based in San Mateo, California and Shanghai, China.

What is TERN-501 and what disease does it target?

TERN-501 is an investigational orally administered thyroid hormone receptor-β (THR-β) agonist developed for the treatment of non-alcoholic steatohepatitis (NASH).

What are the main therapeutic areas Terns Pharmaceuticals focuses on?

Terns Pharmaceuticals focuses on oncology, obesity, and non-alcoholic steatohepatitis (NASH).

What is the significance of TERN-701?

TERN-701 is an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) and represents a novel class of therapy with superior efficacy and safety profiles.

How is Terns Pharmaceuticals funded for its operations?

Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, which they expect to support planned operating expenses into 2026.

What recent achievement has Terns Pharmaceuticals made in clinical trials?

Terns Pharmaceuticals recently announced positive top-line data from its Phase 2a DUET clinical trial of TERN-501 for NASH, showing significant improvements in liver fat content and fibro-inflammation markers.

What is TERN-601 being developed for?

TERN-601 is a small-molecule GLP-1 receptor agonist being developed for the treatment of obesity.

What is the main objective of Terns Pharmaceuticals?

The main objective of Terns Pharmaceuticals is to bring novel, effective small-molecule therapies to market that address significant unmet medical needs globally.

Where can I find more information about Terns Pharmaceuticals' research and development activities?

You can find more information about Terns Pharmaceuticals' research and development activities on their official website at www.ternspharma.com.
Stock TERN logo
Terns Pharmaceuticals, Inc.

Nasdaq:TERN

TERN Rankings

#3385 Ranked by Market Cap
N/A Ranked by Dividends

TERN Stock Data

375.43M
77.27M
0.15%
97.81%
8.99%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY